This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.

Inclusion Criteria:

• Over 18 years old.
• Advanced-stage malignant solid tumor managed in a non-curative context.
• Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.
• Performance status of 0 or 1.
• Patient able to read, write, and understand the French language.
• Patient has read the information sheet and signed the informed consent.
• Patient has social security coverage.

Exclusion Criteria:

• Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.

• Severe or uncontrolled systemic disease.

• Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.

• Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8:

  • Pregnant women, women in labor, and breastfeeding mothers,
  • Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8,
  • Persons admitted to a healthcare or social institution for reasons other than research,
  • Adults unable to give their consent.